Guy A MacGowan1, Stephan Schueler. 1. Departments of Cardiology, Freeman Hospital, Newcastle upon Tyne, UK. guy.macgowan@nuth.nhs.uk
Abstract
PURPOSE OF REVIEW: To review recent publications on right heart failure developing early and late after implantation of left ventricular assist devices (LVAD). RECENT FINDINGS: Whereas use of the newer continuous flow devices is associated with improved outcomes, right heart failure remains a considerable challenge. Recent studies have provided good evidence about predicting right heart failure early after LVADs, though how to predict right heart failure late after LVAD is still unclear as most studies in this area are small single centre experience studies. With respect to medical therapies for treating right heart failure, there is evidence for the use of both nitric oxide and the phosphodiesterase type 5 inhibitor sildenafil in carefully selected patients with secondary pulmonary hypertension who undergo implantation of LVADs. SUMMARY: Despite improved outcomes, right heart failure remains a significant challenge to selecting and managing patients with LVADs, though we do have clearer evidence now for predicting early right heart failure, and treating it in those patients with secondary pulmonary hypertension.
PURPOSE OF REVIEW: To review recent publications on right heart failure developing early and late after implantation of left ventricular assist devices (LVAD). RECENT FINDINGS: Whereas use of the newer continuous flow devices is associated with improved outcomes, right heart failure remains a considerable challenge. Recent studies have provided good evidence about predicting right heart failure early after LVADs, though how to predict right heart failure late after LVAD is still unclear as most studies in this area are small single centre experience studies. With respect to medical therapies for treating right heart failure, there is evidence for the use of both nitric oxide and the phosphodiesterase type 5 inhibitor sildenafil in carefully selected patients with secondary pulmonary hypertension who undergo implantation of LVADs. SUMMARY: Despite improved outcomes, right heart failure remains a significant challenge to selecting and managing patients with LVADs, though we do have clearer evidence now for predicting early right heart failure, and treating it in those patients with secondary pulmonary hypertension.
Authors: Athanasios Tsiouris; Gaetano Paone; Hassan W Nemeh; Jamil Borgi; Celeste T Williams; David E Lanfear; Jeffrey A Morgan Journal: World J Cardiol Date: 2015-11-26
Authors: Haseeb R Jabbar; Ali Abbas; Mustafa Ahmed; Charles T Klodell; Myron Chang; Yunfeng Dai; Peter V Draganov Journal: Dig Dis Sci Date: 2015-06-14 Impact factor: 3.199
Authors: Konstantin Zhigalov; Marcin Szczechowicz; Ahmed Mashhour; Bakitbek K Kadyraliev; Sabreen Mkalaluh; Jerry Easo; Juergen Ennker; Harald C Eichstaedt; Alexander Weymann Journal: J Thorac Dis Date: 2019-04 Impact factor: 2.895
Authors: Ronald D Baxter; Kristen M Tecson; Sasha Still; Justin D G Collier; Joost Felius; Susan M Joseph; Shelley A Hall; Brian Lima Journal: J Thorac Dis Date: 2019-04 Impact factor: 2.895
Authors: Alison Blain; Elizabeth Greally; Steve Laval; Andrew Blamire; Volker Straub; Guy A MacGowan Journal: PLoS One Date: 2013-02-20 Impact factor: 3.240